MICRO-X LIMITED (MX1)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

MX1

MX1 - MICRO-X LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.45
Index:

0

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.027

31 Aug
2026

0.002

OPEN

$0.03

8.00%

HIGH

$0.03

79,046

LOW

$0.03

TARGET
$0.06 122.2% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AVE . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CTE . CU6 . CVB . CYC . EBR . EIQ . EMV . EYE . FPH . IME . IMR . IPD . LDX . NAN . ONE . PCK . PEB . PGC . PME . RAP . RMD . SHG . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
MX1: 1
Title FY25
Actual		 FY26
Actual		 FY27
Forecast		 FY28
Forecast
EPS (cps) xxx - 1.4 - 0.7 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic xxxxxxxxxxxxxxx-1.4
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx15.1 M
Book Value Per Share xxxxxxxxxxxxxxx0.7
Net Operating Cash Flow xxxxxxxxxxxxxxx-8.9 M
Net Profit Margin xxxxxxxxxxxxxxx-65.46 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx-159.38 %
Return on Invested Capital xxxxxxxxxxxxxxx-111.30 %
Return on Assets xxxxxxxxxxxxxxx-47.23 %
Return on Equity xxxxxxxxxxxxxxx-159.38 %
Return on Total Capital xxxxxxxxxxxxxxx-123.83 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-9.1 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx4 M
Long Term Debt xxxxxxxxxxxxxxx3 M
Total Debt xxxxxxxxxxxxxxx7 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx3 M
Price To Book Value xxxxxxxxxxxxxxx5.34

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex xxxxxxxxxxxxxxx0.1 M
Capex % of Sales xxxxxxxxxxxxxxx0.95 %
Cost of Goods Sold xxxxxxxxxxxxxxx24 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx7 M
Research & Development xxxxxxxxxxxxxxx5 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

31/08/2026

3

Downgrade to Hold from Speculative Buy

$0.06

122.22%

Micro-X's FY26 result was slightly ahead of Morgans' expectations, with revenue of $24.1m and an earnings (EBITDA) loss of -$7.9m versus the broker's -$8.5m forecast.

Product sales remain subdued despite increased Rover Plus sales, the broker explains, while project and government-related income continue to provide significant revenue.

Morgans cuts its target to 6c from 8c after increasing its FY27 and FY28 loss forecasts and lowering its FY28 Rover sales assumption to 300 units from 400.

The rating is downgraded to Hold from Speculative Buy, as the analyst awaits evidence the restructured Rover sales strategy can build momentum.

FORECAST
Morgans forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -0.70 cents.
Morgans forecasts a full year FY28 dividend of 0.00 cents and EPS of minus -0.40 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

MX1 STOCK CHART

FNArena News on MX1

1
FNArena Corporate Results Monitor – 31-08-2026

Aug 31 2026 - Australia
2
FNArena Corporate Results Monitor – 23-02-2026

Feb 23 2026 - Australia
3
Rudi’s View: February Favourites & Avoids

Jan 29 2026 - Rudi's View
4
Rudi’s View: A Glass Half-Full Outlook

Sep 03 2025 - Rudi's View
5
FNArena Corporate Results Monitor – 29-08-2025

Aug 29 2025 - Australia

Latest Medical Equipment & Devices News

1
Rudi Interviewed: Bear Market Be Gone

Aug 13 2026 - Rudi's View
2
Are Headwinds Building For ResMed In FY27?

Jul 14 2026 - Australia
3
A Technical Breakout For ResMed

Jul 07 2026 - Technicals
4
Awaiting Catapult Sports’ Fundamental Re-Rating

Jun 15 2026 - Small Caps
5
Treasure Chest: Pro Medicus

Jun 04 2026 - Treasure Chest
6
Cochlear’s Shock Downgrade Raises Concerns

Apr 23 2026 - Australia
7
GLP-1s Drive Strong Quarter For ResMed

Feb 02 2026 - Australia
8
ImpediMed Ready To Scale Up

Dec 16 2025 - Small Caps
9
Fisher & Paykel Healthcare’s Superior Profile

Dec 02 2025 - Australia
10
4DMedical Poised For A Recovery

Nov 25 2025 - Technicals